LX-4211 is primarily used in the research and development of treatments for type 2 diabetes and related metabolic disorders. It functions as a dual inhibitor of sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2), which plays a key role in glucose absorption in the intestines and reabsorption in the kidneys. By inhibiting these transporters, LX-4211 helps reduce blood glucose levels by promoting the excretion of excess glucose through urine and modulating glucose uptake in the gut. This mechanism also contributes to weight loss and improved glycemic control, making it a valuable compound in studying new antidiabetic therapies. Additionally, research suggests potential benefits in reducing postprandial glucose spikes and insulin resistance, supporting its investigation for broader metabolic applications.